Report Open Access

Statistical review of Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Wilkinson, Jack; Dahly, Darren


MARC21 XML Export

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="041" ind1=" " ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Randomized Clinical Trials</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">COVID-19</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Antiviral</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Favipiravir</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Arbidol</subfield>
  </datafield>
  <controlfield tag="005">20200402130324.0</controlfield>
  <controlfield tag="001">3734198</controlfield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">HRB Clinical Research Facility - Cork. HRB Trial Methodology Research Network. University College Cork School of Public Health</subfield>
    <subfield code="a">Dahly, Darren</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">589943</subfield>
    <subfield code="z">md5:caec1dce19b27f4f178192988f71de3e</subfield>
    <subfield code="u">https://zenodo.org/record/3734198/files/Review 20_03_21_001(1).pdf</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2020-03-31</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">openaire</subfield>
    <subfield code="p">user-covid-19-tx-rct-stats-review</subfield>
    <subfield code="p">user-zenodo</subfield>
    <subfield code="p">user-covid-19</subfield>
    <subfield code="o">oai:zenodo.org:3734198</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="u">Centre for Biostatistics, Manchester Academic Health Science Centre, University of Manchester.</subfield>
    <subfield code="a">Wilkinson, Jack</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Statistical review of Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-covid-19</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-covid-19-tx-rct-stats-review</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-zenodo</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="u">https://creativecommons.org/licenses/by/4.0/legalcode</subfield>
    <subfield code="a">Creative Commons Attribution 4.0 International</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2">opendefinition.org</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">&lt;p&gt;The following review has been prepared in collaboration with members of the MRC-NIHR Trials Methodology Research Partnership. The reviewers named above, and other, unnamed discussants of the paper, are all qualified statisticians with experience in clinical trials. Our objective is to provide a rapid review of publications, preprints and protocols from clinical trials of COVID-19 treatments, independent of journal specific review processes. We aim to provide timely, constructive, focused, clear advice aimed at improving both the research outputs under review, as well as future studies. Given our collective expertise (clinical trial statistics) our reviews focus on the designs of the trials and other statistical content (methods, presentation and accuracy of results, inferences). Here we review &lt;em&gt;Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial,&lt;/em&gt; by Chen et al. &lt;a href="https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2"&gt;https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2&lt;/a&gt;&lt;/p&gt;</subfield>
  </datafield>
  <datafield tag="773" ind1=" " ind2=" ">
    <subfield code="n">doi</subfield>
    <subfield code="i">reviews</subfield>
    <subfield code="a">10.1101/2020.03.17.20037432</subfield>
  </datafield>
  <datafield tag="773" ind1=" " ind2=" ">
    <subfield code="n">doi</subfield>
    <subfield code="i">isVersionOf</subfield>
    <subfield code="a">10.5281/zenodo.3734197</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.5281/zenodo.3734198</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">report</subfield>
  </datafield>
</record>
4,299
2,536
views
downloads
All versions This version
Views 4,2994,299
Downloads 2,5362,536
Data volume 1.5 GB1.5 GB
Unique views 3,7793,779
Unique downloads 2,3102,310

Share

Cite as